Multimerization of anti‐(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers

The construction of antibody fragments has the potential to reduce the high cost of therapeutic antibody production, but the structures of these fragments, with monovalency and the lack of an Fc region, can lead to reduced function. Multimerization is one strategy for recovering function that also y...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The FEBS journal 2013-10, Vol.280 (19), p.4816-4826
Hauptverfasser: Asano, Ryutaro, Hagiwara, Yasuyo, Koyama, Noriaki, Masakari, Yosuke, Orimo, Ryota, Arai, Kyoko, Ogata, Hiromi, Furumoto, Shozo, Umetsu, Mitsuo, Kumagai, Izumi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4826
container_issue 19
container_start_page 4816
container_title The FEBS journal
container_volume 280
creator Asano, Ryutaro
Hagiwara, Yasuyo
Koyama, Noriaki
Masakari, Yosuke
Orimo, Ryota
Arai, Kyoko
Ogata, Hiromi
Furumoto, Shozo
Umetsu, Mitsuo
Kumagai, Izumi
description The construction of antibody fragments has the potential to reduce the high cost of therapeutic antibody production, but the structures of these fragments, with monovalency and the lack of an Fc region, can lead to reduced function. Multimerization is one strategy for recovering function that also yields better tumor‐to‐blood ratios than IgGs or monomeric antibody fragments because of rapid tumor uptake and clearance. Here, we constructed single‐chain variable fragment (scFv) multimers by modifying the linker length and domain order of humanized anti‐(epidermal growth factor receptor) IgG 528 (h528) and tested their ability to inhibit tumor growth. h528 scFv multimers, expressed using a bacterial expression system, were successfully fractionated and inhibited cancer growth in a multimerization‐dependent manner, whereas the h528 scFv monomer showed no inhibition. h528 scFv trimers with variable heavy–light domain order and no linkers showed the highest in vitro and in vivo antitumor effects, which were comparable with those of the approved anti‐(epidermal growth factor receptor) therapeutic IgG Cetuximab and Panitumumab. The trimers were also structurally stable in vitro and in vivo, which may be attributable to a strong interaction between the variable heavy and variable light domains of h528 Fv. Thus, h528 scFv multimers, especially trimers, are attractive as the next generation of anti‐(epidermal growth factor receptor) therapeutic IgG and offer the possibility of low‐cost production. We constructed single‐chain variable fragment (scFv) multimers by modifying the linker length and domain order of the humanized anti‐EGFR antibody 528 (h528) and tested their ability to inhibit tumor growth. The h528 scFv multimers, expressed using a bacterial expression system, were successfully fractionated and inhibited cancer growth in a multimerization‐dependent manner, whereas the h528 scFv monomer showed no inhibition.
doi_str_mv 10.1111/febs.12451
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1434744561</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3075718211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4591-dd5756b9ee1bd6e69b983126b6d5ca4e528203f07c802fea57d8af21b37371b13</originalsourceid><addsrcrecordid>eNp9kc1KJDEQx8OirF972QdYAl5UGLfz1R_eXHFUUPagwt6adFKZiXS6xyS9oicfQV_RJzHjjB48WJcqil_9KPgj9JNk-yTVbwNN2CeUC_INrZOC0xHPRbnyMfN_a2gjhJssY4JX1Xe0RllZZZwU6-j5YmijdeDtg4y273BvsOyifXl82oGZ1eCdbPHE93dxio1UsffYg4JZGnbx2eQEGy8nDroYsO30oCCk-zdFHFyCwRhQ8QDHKWAlA2CTltPByc4-gMaCljio8X_sln-ELbRqZBvgx7Jvouvx8dXR6ej878nZ0eH5SHFRkZHWohB5UwGQRueQV01VMkLzJtdCSQ5JTDNmskKVGTUgRaFLaShpWMEK0hC2iXYW3pnvbwcIsXY2KGhb2UE_hJpwxgvORT5Htz-hN_3gu_TdnGKClLTiidpbUMr3IXgw9cxbJ_19TbJ6HlQ9D6p-CyrBv5bKoXGgP9D3ZBJAFsCdbeH-C1U9Pv5zuZC-Ak6Nn9w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1433518294</pqid></control><display><type>article</type><title>Multimerization of anti‐(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers</title><source>Wiley Free Content</source><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Free Full-Text Journals in Chemistry</source><creator>Asano, Ryutaro ; Hagiwara, Yasuyo ; Koyama, Noriaki ; Masakari, Yosuke ; Orimo, Ryota ; Arai, Kyoko ; Ogata, Hiromi ; Furumoto, Shozo ; Umetsu, Mitsuo ; Kumagai, Izumi</creator><creatorcontrib>Asano, Ryutaro ; Hagiwara, Yasuyo ; Koyama, Noriaki ; Masakari, Yosuke ; Orimo, Ryota ; Arai, Kyoko ; Ogata, Hiromi ; Furumoto, Shozo ; Umetsu, Mitsuo ; Kumagai, Izumi</creatorcontrib><description>The construction of antibody fragments has the potential to reduce the high cost of therapeutic antibody production, but the structures of these fragments, with monovalency and the lack of an Fc region, can lead to reduced function. Multimerization is one strategy for recovering function that also yields better tumor‐to‐blood ratios than IgGs or monomeric antibody fragments because of rapid tumor uptake and clearance. Here, we constructed single‐chain variable fragment (scFv) multimers by modifying the linker length and domain order of humanized anti‐(epidermal growth factor receptor) IgG 528 (h528) and tested their ability to inhibit tumor growth. h528 scFv multimers, expressed using a bacterial expression system, were successfully fractionated and inhibited cancer growth in a multimerization‐dependent manner, whereas the h528 scFv monomer showed no inhibition. h528 scFv trimers with variable heavy–light domain order and no linkers showed the highest in vitro and in vivo antitumor effects, which were comparable with those of the approved anti‐(epidermal growth factor receptor) therapeutic IgG Cetuximab and Panitumumab. The trimers were also structurally stable in vitro and in vivo, which may be attributable to a strong interaction between the variable heavy and variable light domains of h528 Fv. Thus, h528 scFv multimers, especially trimers, are attractive as the next generation of anti‐(epidermal growth factor receptor) therapeutic IgG and offer the possibility of low‐cost production. We constructed single‐chain variable fragment (scFv) multimers by modifying the linker length and domain order of the humanized anti‐EGFR antibody 528 (h528) and tested their ability to inhibit tumor growth. The h528 scFv multimers, expressed using a bacterial expression system, were successfully fractionated and inhibited cancer growth in a multimerization‐dependent manner, whereas the h528 scFv monomer showed no inhibition.</description><identifier>ISSN: 1742-464X</identifier><identifier>EISSN: 1742-4658</identifier><identifier>DOI: 10.1111/febs.12451</identifier><identifier>PMID: 23890417</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Animals ; antitumor effect ; Blotting, Western ; Cell Line, Tumor ; Cell Survival - drug effects ; EGFR ; Epidermal growth factor ; Female ; Humans ; Immunoglobulin G - metabolism ; Immunoglobulin G - pharmacology ; Immunoglobulin G - therapeutic use ; Male ; Mice ; Mice, SCID ; Receptor, Epidermal Growth Factor - immunology ; ScFv ; ScFv multimer ; Single-Chain Antibodies - metabolism ; Single-Chain Antibodies - pharmacology ; Single-Chain Antibodies - therapeutic use ; Triabody ; Tumors</subject><ispartof>The FEBS journal, 2013-10, Vol.280 (19), p.4816-4826</ispartof><rights>2013 FEBS</rights><rights>2013 FEBS.</rights><rights>Copyright © 2013 Federation of European Biochemical Societies</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4591-dd5756b9ee1bd6e69b983126b6d5ca4e528203f07c802fea57d8af21b37371b13</citedby><cites>FETCH-LOGICAL-c4591-dd5756b9ee1bd6e69b983126b6d5ca4e528203f07c802fea57d8af21b37371b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ffebs.12451$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ffebs.12451$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23890417$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Asano, Ryutaro</creatorcontrib><creatorcontrib>Hagiwara, Yasuyo</creatorcontrib><creatorcontrib>Koyama, Noriaki</creatorcontrib><creatorcontrib>Masakari, Yosuke</creatorcontrib><creatorcontrib>Orimo, Ryota</creatorcontrib><creatorcontrib>Arai, Kyoko</creatorcontrib><creatorcontrib>Ogata, Hiromi</creatorcontrib><creatorcontrib>Furumoto, Shozo</creatorcontrib><creatorcontrib>Umetsu, Mitsuo</creatorcontrib><creatorcontrib>Kumagai, Izumi</creatorcontrib><title>Multimerization of anti‐(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers</title><title>The FEBS journal</title><addtitle>FEBS J</addtitle><description>The construction of antibody fragments has the potential to reduce the high cost of therapeutic antibody production, but the structures of these fragments, with monovalency and the lack of an Fc region, can lead to reduced function. Multimerization is one strategy for recovering function that also yields better tumor‐to‐blood ratios than IgGs or monomeric antibody fragments because of rapid tumor uptake and clearance. Here, we constructed single‐chain variable fragment (scFv) multimers by modifying the linker length and domain order of humanized anti‐(epidermal growth factor receptor) IgG 528 (h528) and tested their ability to inhibit tumor growth. h528 scFv multimers, expressed using a bacterial expression system, were successfully fractionated and inhibited cancer growth in a multimerization‐dependent manner, whereas the h528 scFv monomer showed no inhibition. h528 scFv trimers with variable heavy–light domain order and no linkers showed the highest in vitro and in vivo antitumor effects, which were comparable with those of the approved anti‐(epidermal growth factor receptor) therapeutic IgG Cetuximab and Panitumumab. The trimers were also structurally stable in vitro and in vivo, which may be attributable to a strong interaction between the variable heavy and variable light domains of h528 Fv. Thus, h528 scFv multimers, especially trimers, are attractive as the next generation of anti‐(epidermal growth factor receptor) therapeutic IgG and offer the possibility of low‐cost production. We constructed single‐chain variable fragment (scFv) multimers by modifying the linker length and domain order of the humanized anti‐EGFR antibody 528 (h528) and tested their ability to inhibit tumor growth. The h528 scFv multimers, expressed using a bacterial expression system, were successfully fractionated and inhibited cancer growth in a multimerization‐dependent manner, whereas the h528 scFv monomer showed no inhibition.</description><subject>Animals</subject><subject>antitumor effect</subject><subject>Blotting, Western</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>EGFR</subject><subject>Epidermal growth factor</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin G - metabolism</subject><subject>Immunoglobulin G - pharmacology</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, SCID</subject><subject>Receptor, Epidermal Growth Factor - immunology</subject><subject>ScFv</subject><subject>ScFv multimer</subject><subject>Single-Chain Antibodies - metabolism</subject><subject>Single-Chain Antibodies - pharmacology</subject><subject>Single-Chain Antibodies - therapeutic use</subject><subject>Triabody</subject><subject>Tumors</subject><issn>1742-464X</issn><issn>1742-4658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1KJDEQx8OirF972QdYAl5UGLfz1R_eXHFUUPagwt6adFKZiXS6xyS9oicfQV_RJzHjjB48WJcqil_9KPgj9JNk-yTVbwNN2CeUC_INrZOC0xHPRbnyMfN_a2gjhJssY4JX1Xe0RllZZZwU6-j5YmijdeDtg4y273BvsOyifXl82oGZ1eCdbPHE93dxio1UsffYg4JZGnbx2eQEGy8nDroYsO30oCCk-zdFHFyCwRhQ8QDHKWAlA2CTltPByc4-gMaCljio8X_sln-ELbRqZBvgx7Jvouvx8dXR6ej878nZ0eH5SHFRkZHWohB5UwGQRueQV01VMkLzJtdCSQ5JTDNmskKVGTUgRaFLaShpWMEK0hC2iXYW3pnvbwcIsXY2KGhb2UE_hJpwxgvORT5Htz-hN_3gu_TdnGKClLTiidpbUMr3IXgw9cxbJ_19TbJ6HlQ9D6p-CyrBv5bKoXGgP9D3ZBJAFsCdbeH-C1U9Pv5zuZC-Ak6Nn9w</recordid><startdate>201310</startdate><enddate>201310</enddate><creator>Asano, Ryutaro</creator><creator>Hagiwara, Yasuyo</creator><creator>Koyama, Noriaki</creator><creator>Masakari, Yosuke</creator><creator>Orimo, Ryota</creator><creator>Arai, Kyoko</creator><creator>Ogata, Hiromi</creator><creator>Furumoto, Shozo</creator><creator>Umetsu, Mitsuo</creator><creator>Kumagai, Izumi</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201310</creationdate><title>Multimerization of anti‐(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers</title><author>Asano, Ryutaro ; Hagiwara, Yasuyo ; Koyama, Noriaki ; Masakari, Yosuke ; Orimo, Ryota ; Arai, Kyoko ; Ogata, Hiromi ; Furumoto, Shozo ; Umetsu, Mitsuo ; Kumagai, Izumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4591-dd5756b9ee1bd6e69b983126b6d5ca4e528203f07c802fea57d8af21b37371b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>antitumor effect</topic><topic>Blotting, Western</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>EGFR</topic><topic>Epidermal growth factor</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin G - metabolism</topic><topic>Immunoglobulin G - pharmacology</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, SCID</topic><topic>Receptor, Epidermal Growth Factor - immunology</topic><topic>ScFv</topic><topic>ScFv multimer</topic><topic>Single-Chain Antibodies - metabolism</topic><topic>Single-Chain Antibodies - pharmacology</topic><topic>Single-Chain Antibodies - therapeutic use</topic><topic>Triabody</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Asano, Ryutaro</creatorcontrib><creatorcontrib>Hagiwara, Yasuyo</creatorcontrib><creatorcontrib>Koyama, Noriaki</creatorcontrib><creatorcontrib>Masakari, Yosuke</creatorcontrib><creatorcontrib>Orimo, Ryota</creatorcontrib><creatorcontrib>Arai, Kyoko</creatorcontrib><creatorcontrib>Ogata, Hiromi</creatorcontrib><creatorcontrib>Furumoto, Shozo</creatorcontrib><creatorcontrib>Umetsu, Mitsuo</creatorcontrib><creatorcontrib>Kumagai, Izumi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The FEBS journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Asano, Ryutaro</au><au>Hagiwara, Yasuyo</au><au>Koyama, Noriaki</au><au>Masakari, Yosuke</au><au>Orimo, Ryota</au><au>Arai, Kyoko</au><au>Ogata, Hiromi</au><au>Furumoto, Shozo</au><au>Umetsu, Mitsuo</au><au>Kumagai, Izumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multimerization of anti‐(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers</atitle><jtitle>The FEBS journal</jtitle><addtitle>FEBS J</addtitle><date>2013-10</date><risdate>2013</risdate><volume>280</volume><issue>19</issue><spage>4816</spage><epage>4826</epage><pages>4816-4826</pages><issn>1742-464X</issn><eissn>1742-4658</eissn><abstract>The construction of antibody fragments has the potential to reduce the high cost of therapeutic antibody production, but the structures of these fragments, with monovalency and the lack of an Fc region, can lead to reduced function. Multimerization is one strategy for recovering function that also yields better tumor‐to‐blood ratios than IgGs or monomeric antibody fragments because of rapid tumor uptake and clearance. Here, we constructed single‐chain variable fragment (scFv) multimers by modifying the linker length and domain order of humanized anti‐(epidermal growth factor receptor) IgG 528 (h528) and tested their ability to inhibit tumor growth. h528 scFv multimers, expressed using a bacterial expression system, were successfully fractionated and inhibited cancer growth in a multimerization‐dependent manner, whereas the h528 scFv monomer showed no inhibition. h528 scFv trimers with variable heavy–light domain order and no linkers showed the highest in vitro and in vivo antitumor effects, which were comparable with those of the approved anti‐(epidermal growth factor receptor) therapeutic IgG Cetuximab and Panitumumab. The trimers were also structurally stable in vitro and in vivo, which may be attributable to a strong interaction between the variable heavy and variable light domains of h528 Fv. Thus, h528 scFv multimers, especially trimers, are attractive as the next generation of anti‐(epidermal growth factor receptor) therapeutic IgG and offer the possibility of low‐cost production. We constructed single‐chain variable fragment (scFv) multimers by modifying the linker length and domain order of the humanized anti‐EGFR antibody 528 (h528) and tested their ability to inhibit tumor growth. The h528 scFv multimers, expressed using a bacterial expression system, were successfully fractionated and inhibited cancer growth in a multimerization‐dependent manner, whereas the h528 scFv monomer showed no inhibition.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>23890417</pmid><doi>10.1111/febs.12451</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1742-464X
ispartof The FEBS journal, 2013-10, Vol.280 (19), p.4816-4826
issn 1742-464X
1742-4658
language eng
recordid cdi_proquest_miscellaneous_1434744561
source Wiley Free Content; MEDLINE; IngentaConnect Free/Open Access Journals; Wiley Online Library Journals Frontfile Complete; Free Full-Text Journals in Chemistry
subjects Animals
antitumor effect
Blotting, Western
Cell Line, Tumor
Cell Survival - drug effects
EGFR
Epidermal growth factor
Female
Humans
Immunoglobulin G - metabolism
Immunoglobulin G - pharmacology
Immunoglobulin G - therapeutic use
Male
Mice
Mice, SCID
Receptor, Epidermal Growth Factor - immunology
ScFv
ScFv multimer
Single-Chain Antibodies - metabolism
Single-Chain Antibodies - pharmacology
Single-Chain Antibodies - therapeutic use
Triabody
Tumors
title Multimerization of anti‐(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T08%3A01%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multimerization%20of%20anti%E2%80%90(epidermal%20growth%20factor%20receptor)%20IgG%20fragments%20induces%20an%20antitumor%20effect:%20the%20case%20for%20humanized%20528%20scFv%20multimers&rft.jtitle=The%20FEBS%20journal&rft.au=Asano,%20Ryutaro&rft.date=2013-10&rft.volume=280&rft.issue=19&rft.spage=4816&rft.epage=4826&rft.pages=4816-4826&rft.issn=1742-464X&rft.eissn=1742-4658&rft_id=info:doi/10.1111/febs.12451&rft_dat=%3Cproquest_cross%3E3075718211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1433518294&rft_id=info:pmid/23890417&rfr_iscdi=true